Table 2 Descriptive Information from Sample RCTs (N = 104)a
Medication class, no. (%) | Results |
|---|---|
Hepatitis C antivirals | 27 (26) |
Antibacterials | 26 (25) |
Antiretrovirals | 22 (21) |
Antimalarials | 6 (6) |
Antifungals | 4 (4) |
Antimycobacterials | 4 (4) |
Miscellaneous antivirals | 4 (4) |
Neuraminidase inhibitors | 4 (4) |
Antihelminthics | 2 (2) |
Antiprotozoals | 2 (2) |
Nucleosides and nucleotides | 2 (2) |
Monoclonal antibodies | 1 (1) |
Treatment groups, no. (%) | |
2 | 64 (62) |
3 | 23 (22) |
4 | 10 (10) |
5 | 3 (3) |
6 | 1 (1) |
8 | 2 (2) |
14 | 1 (1) |
Study design, no. (%) | |
Superiority | 74 (71) |
Non-inferiority | 30 (29) |
Enrolment, median (IQR) | 395 (156 to 724) |
Blinding, no. (%) | |
Open-label | 48 (46) |
Single | 1 (1) |
Double | 52 (50) |
Not described | 3 (3) |
Endpoint type, no. (%) | |
Nominal | 71 (68) |
Continuous | 32 (31) |
Unable to determine | 1 (1) |
Result type, no. (%) | |
Favorable | 79 (76) |
Unfavorable | 25 (24) |